Wockhardt is currently trading at Rs. 917.35, up by 2.45 points or 0.27% from its previous closing of Rs. 914.90 on the BSE.
The scrip opened at Rs. 901.10 and has touched a high and low of Rs. 937.40 and Rs. 732.00 respectively. So far 149220 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2166.05 on 12-Mar-2013 and a 52 week low of Rs. 732.00 on 08-Jul-2013.
Last one week high and low of the scrip stood at Rs. 1130.00 and Rs. 732.00 respectively. The current market cap of the company is Rs. 10081.67 crore.
The promoters holding in the company stood at 73.54 % while Institutions and Non-Institutions held 12.32 % and 14.00 % respectively.
Wockhardt has received an ‘import alert’ from UK medicines and Healthcare Products Regulatory Agency (MHRA) for export-oriented plant at Waluj in Aurangabad. Import alert was made due to certain deviations from its quality manufacturing norms at the company’s plant at Waluj. Earlier in May, the company received an ‘import alert’ from USFDA on one of its manufacturing unit located in Waluj near Aurangabad.
The impact of the import alert on the revenues is estimated to be in the range of $100 million on an annualised basis. The company is planning to shift production elsewhere and restore manufacturing within six to nine months.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |